[Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients].
Seventy nine advanced cancer patients in a clinical trial were treated with LAK/IL-2 combining with Lycium Barbarum polysaccharides (LBP). Initial results of the treatment from 75 evaluable patients indicated that objective regression of cancer was achieved in patients with malignant melanoma, renal cell carcinoma, colorectal carcinoma, lung cancer, nasopharyngeal carcinoma, malignant hydrothorax. The response rate of patients treated with LAK/IL-2 plus LBP was 40.9% while that of patients treated with LAK/IL-2 was 16.1% (P < 0.05). The mean remission in patients treated with LAK/IL-2 plus LBP also lasted significantly longer. LAK/IL-2 plus LBP treatment led to more marked increase in NK and LAK cell activity than LAK/IL-2 without LBP. The results indicate that LBP can be used as an adjuvant in the biotherapy of cancer.
Cao
G W
GW
Second Military Medical University, Department of Microbiology, Shanghai.
Yang
W G
WG
Du
P
P
D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000628:therapy; D003131:Combined Modality Therapy; D004365:Drugs, Chinese Herbal / Q000737:chemistry*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000628:therapy*; D008545:Melanoma / Q000628:therapy; D011134:Polysaccharides / Q000627:therapeutic use*
D004365:Drugs, Chinese Herbal; D007376:Interleukin-2; D011134:Polysaccharides